Pancreatic Hormone-Expressing Cell Differentiation Protocol
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to produce reliable and scalable populations of glucose-responsive insulin-producing cells derived from human embryonic stem cells for effective treatment of insulin-dependent diabetes.
Innovation Solution
Development of cell cultures comprising human pancreatic islet hormone-expressing cells and endocrine precursor cells, where the cells are differentiated from human embryonic stem cells through specific stages using growth factors and inhibitors, allowing for the enrichment of pancreatic islet hormone-expressing cells and endocrine precursor cells, and their subsequent use in in vivo insulin production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If human embryonic stem cells are differentiated into pancreatic endocrine cells, then insulin-producing cells can be generated for diabetes treatment, but the production of reliable and scalable populations with glucose-responsive insulin secretion remains unsuccessful
Solution Approach 1:
The differentiation process is divided into distinct temporal stages: early endoderm formation (days 0-7), pancreatic endoderm specification (days 7-14), and endocrine cell differentiation (days 14-21). Each stage uses specific growth factors and inhibitors to achieve reliable conversion at each step, ultimately producing scalable populations of functional insulin-producing cells.
Solution Approach 2:
The method performs preliminary differentiation steps to generate endoderm and pancreatic endoderm cells before final endocrine cell differentiation. This preliminary action ensures that the cellular foundation is properly established with appropriate gene expression profiles, enabling reliable and scalable production of functional insulin-producing cells in subsequent steps.
2Reliability
If cell cultures are enriched for pancreatic islet hormone-expressing cells, then functional insulin production capability is improved, but the complexity of the differentiation protocol increases
Solution Approach 1:
The differentiation protocol maintains continuous useful action through sequential addition of growth factors and inhibitors at each temporal stage. Growth factors such as Activin A, FGF10, and retinoic acid are continuously applied in a coordinated manner to drive consistent differentiation toward functional insulin-producing cells, enriching the population while managing protocol complexity through systematic progression.
Solution Approach 2:
The method systematically changes parameters including growth factor concentration, inhibitor dosage, and culture conditions at each temporal stage. By optimizing these parameters sequentially—adjusting Activin A concentration during early endoderm formation, FGF10 levels during pancreatic endoderm specification, and retinoic acid dosing during endocrine differentiation—the protocol enriches functional cells while managing complexity through parameter optimization rather than procedural complexity.
Data Source
AI summary
Disclosed herein are methods of producing pancreatic hormone-expressing cells by first differentiating pluripotent cells in cell culture so as to produce endodermal cells, the endodermal cells being competent to further differentiate into hormone-expressing cells capable of secreting at least one pancreatic hormone in response to a physiological signal, and then, transplanting the cultured endodermal cells into an organism, such as an organism in need of an endocrine cell therapy.